Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021Show others and affiliations
2022 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 12, no 1, article id 10816
Article in journal (Refereed) Published
Abstract [en]
A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April–May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
Place, publisher, year, edition, pages
Nature Publishing Group, 2022. Vol. 12, no 1, article id 10816
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:umu:diva-203320DOI: 10.1038/s41598-022-15183-wISI: 000815641500016PubMedID: 35752708Scopus ID: 2-s2.0-85132991961OAI: oai:DiVA.org:umu-203320DiVA, id: diva2:1728315
Funder
Public Health Agency of Sweden , S2020/0281/FSPublic Health Agency of Sweden , S2020/08532 FS2023-01-182023-01-182023-01-18Bibliographically approved